Terms ending in 2037
Every in-force patent on Cellectis's record whose computed term ends in 2037, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,752,670 | ANTI-GD3 Specific Chimeric Antigen Receptors for Cancer Immunotherapy In force · High confidence | Cellectis | In force | High confidence | |
| US 10,259,876 | Chimeric Antigen Receptors Targeting Epidermal Growth Factor Receptor Variant III In force · High confidence | Pfizer Inc. | In force | High confidence | |
| US 10,550,402 | Modifying Soybean Oil Composition Through Targeted Knockout of the FAD3A/B/C Genes In force · High confidence | Cellectis | In force | High confidence | |
| US 11,987,639 | Trophoblast Glycoprotein (5T4, TPBG) Specific Chimeric Antigen Receptors for Cancer Immunotherapy In force · High confidence | Cellectis | In force | High confidence | |
| US 12,171,820 | Method for Generating Immune Cells Resistant to Arginine And/Or Tryptophan Depleted Microenvironment In force · High confidence | Cellectis | In force | High confidence | |
| US 10,894,093 | A Method of Engineering Drug-Specific Hypersensitive T-Cells for Immunotherapy by Gene Inactivation In force · High confidence | Cellectis | In force | High confidence | |
| US 11,674,155 | Sequential Gene Editing in Primary Immune Cells In force · High confidence | Cellectis | In force | High confidence | |
| US 11,466,291 | Sequential Gene Editing in Primary Immune Cells In force · High confidence | Cellectis | In force | High confidence | |
| US 12,391,933 | Targeted Gene Insertion for Improved Immune Cells Therapy In force · High confidence | Cellectis | In force | High confidence | |
| US 10,988,542 | Chimeric Antigen Receptors with Integrated Controllable Functions In force · High confidence | Cellectis | In force | High confidence | |
| 1 more term end in 2037 · Pro | |||||
10 of 11 patents shown. Soonest term end first, then patent number.
Pro members see all 11.
10 of these are in force and held by Cellectis.
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.